[1]
J. I. Silverberg, “Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis”, Acta Derm Venereol, vol. 101, no. 11, p. adv00585, Nov. 2021.